The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 14, 2010

Filed:

Oct. 12, 2004
Applicants:

Jian LI, West Roxbury, MA (US);

Jue-lon Shie, Acton, MA (US);

Roger J. Laham, Brookline, MA (US);

Inventors:

Jian Li, West Roxbury, MA (US);

Jue-Lon Shie, Acton, MA (US);

Roger J. Laham, Brookline, MA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 48/00 (2006.01); C12N 15/00 (2006.01); C12N 15/06 (2006.01); C12N 15/07 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention features methods and compositions for preventing, reducing, or treating hypoxia and pathological disorders involving abnormal angiogenesis (e.g., conditions involving decreases or increases in blood flow, respectively). Where an increase in angiogenesis is desired, the mammal being treated for an ischemic condition is provided with Related Transcriptional Enhancer Factor-1 (RTEF-1; as a recombinant polypeptide or as an expression vector) sufficient to increase expression of VEGF, FGFR, or COX-2. This results in a concomitant increase in angiogenesis. Conversely, a mammal being treated for a hypervascular condition is administered a composition that reduces the levels of RTEF-1, thereby reducing the expression of VEGF, FGFR, or COX-2, which results in a decrease in angiogenesis. Also disclosed are screening methods that make use of RTEF-1 for the identification of novel therapeutics for the treatment, prevention, or reduction of pathological disorders involving hypoxia or abnormal angiogenesis, namely, ischemic or hypervascular conditions.


Find Patent Forward Citations

Loading…